ALT240927P7500
- 0.51
- +0.04+8.51%
Altimmune Newsroom
Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
JMP Securities analyst Jonathan Wolleben maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $24.According to TipRanks data, the analyst has a success rate of 43.9%
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
Altimmune Spikes After Presenting Data for Obesity Drug
Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Daily Option Recap | Nvidia rebounded before the market, one call option was thrown out with a bid of $20 million for bullish; Tesla fell more than 8% last Friday, multiple end-of-the-world put options made over 20 times profit.
The day before the iPhone 16 launch event, Apple's implied volatility rose to 58.71%; after the non-farm payroll release, EEM options trading became active, with differences between long and short positions among large traders.
Express News | Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60TH Annual Meeting of the European Association for the Study of Diabetes
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market
Decoding 4 Analyst Evaluations For Altimmune
HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright analyst Patrick Trucchio maintains $Altimmune(ALT.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 30.3%
Optimistic Buy Rating for Altimmune's Pemvidutide on Promising Clinical and Strategic Developments
B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target
Altimmune Analyst Ratings
Buy Rating on Altimmune: Pemvidutide's Market Potential in Obesity and Beyond
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript